APO Research
Talk to an analyst

APO RESEARCH · REPORT

Tofacitinib

Compare research editions
View pricing & licenses

Selected research

Market Outlook & Growth Opportunities

Global Tofacitinib Market Outlook and Growth Opportunities 2026

23 December 2025192 pages

Choose your research edition.

Industry ResearchTofacitinib Industry Research Report 2026119 pages · $2,950 USDIndustry Growth & TrendsGlobal Tofacitinib Industry Growth and Trends Forecast to 203298 pages · $3,450 USDMarket StructureGlobal Tofacitinib Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032182 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Tofacitinib Market Outlook and Growth Opportunities 2026192 pages · $4,250 USDMarket Analysis & ForecastGlobal Tofacitinib Market Analysis and Forecast 2026-2032190 pages · $4,950 USD

Market perspective

The global Tofacitinib market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a compound annual growth rate (CAGR) of % over 2026-2032.

The North America market for Tofacitinib is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The Europe market for Tofacitinib is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for Tofacitinib is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

In China, the Tofacitinib market is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Major global companies in the Tofacitinib market include Pfizer, Globe Pharmaceuticals, Drug International, Delta Pharma Limited and Beacon Pharmaceuticals, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.

This report provides an overview of the global Tofacitinib market in terms of sales, revenue, and price, analyzing global market trends using historical revenue and sales data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of Tofacitinib and sales in major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents Tofacitinib sales, revenue, market share, and industry ranking for the main manufacturers for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

In addition, the report analyzes segment data by Type and Application—covering sales, revenue, and price—for 2021-2032, and evaluates and forecasts the Tofacitinib market size, projected growth trends, production technologies, key applications, and end-use industries.

Tofacitinib Segment by Company

Pfizer

Globe Pharmaceuticals

Drug International

Delta Pharma Limited

Beacon Pharmaceuticals

Tofacitinib Segment by Type

5mg*60 Tablets

5mg*30 Tablets

5mg*14 Tablets

5mg*10 Tablets

10mg*14 Tablets

10mg*10 Tablets

Tofacitinib Segment by Application

Psoriasis

Rheumatoid Arthritis

Ulcerative Colitis

Others

Tofacitinib Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Study Objectives

1. To analyze and research the global Tofacitinib status and future forecast, involving, sales, revenue, growth rate (CAGR), market share, historical and forecast.

2. To present the key manufacturers, sales, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions Tofacitinib market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify Tofacitinib significant trends, drivers, influence factors in global and regions.

6. To analyze Tofacitinib competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Tofacitinib market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Tofacitinib and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Tofacitinib.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Provides an overview of the Tofacitinib market, including product definition, global market growth prospects, sales value, sales volume, and average price forecasts (2021-2032).

Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global Tofacitinib industry.

Chapter 3: Detailed analysis of Tofacitinib manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales and value of Tofacitinib in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of each country in the world.

Chapter 7: Sales and value of Tofacitinib in country level. It provides sigmate data by type, and by application for each country/region.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.

Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.

Chapter 10: Concluding Insights.

More report detail

Tables and figures
List of Tables Table 1. Tofacitinib Industry Trends Table 2. Tofacitinib Industry Drivers Table 3. Tofacitinib Industry Opportunities and Challenges Table 4. Tofacitinib Industry Restraints Table 5. Global Tofacitinib Revenue by Company (US$ Million) & (2021-2026) Table 6. Global Tofacitinib Revenue Share by Company (2021-2026) Table 7. Global Tofacitinib Sales Volume by Company (k pcs) & (2021-2026) Table 8. Global Tofacitinib Sales Volume Share by Company (2021-2026) Table 9. Global Tofacitinib Average Price (US$/pcs) of Company (2021-2026) Table 10. Global Tofacitinib Company Ranking, (2024-2026) & (USD Million) Table 11. Global Tofacitinib Key Company Manufacturing Base & Headquarters Table 12. Global Tofacitinib Company, Product Type & Application Table 13. Global Tofacitinib Company Establishment Date Table 14. Global Company Market Concentration Ratio (CR5 and HHI) Table 15. Global Tofacitinib by Company Type (Tier 1, Tier 2, and Tier 3) & (Based on Revenue of 2025) Table 16. Mergers & Acquisitions, Expansion Table 17. Significant Companies of 5mg*60 Tablets Table 18. Significant Companies of 5mg*30 Tablets Table 19. Significant Companies of 5mg*14 Tablets Table 20. Significant Companies of 5mg*10 Tablets Table 21. Significant Companies of 10mg*14 Tablets Table 22. Significant Companies of 10mg*10 Tablets Table 23. Global Tofacitinib Sales Volume by Type 2021 VS 2025 VS 2032 (k pcs) Table 24. Global Tofacitinib Sales Volume by Type (2021-2026) & (k pcs) Table 25. Global Tofacitinib Sales Volume by Type (2027-2032) & (k pcs) Table 26. Global Tofacitinib Sales Volume Share by Type (2021-2026) Table 27. Global Tofacitinib Sales Volume Share by Type (2027-2032) Table 28. Global Tofacitinib Sales Value by Type 2021 VS 2025 VS 2032 (US$ Million) Table 29. Global Tofacitinib Sales Value by Type (2021-2026) & (US$ Million) Table 30. Global Tofacitinib Sales Value by Type (2027-2032) & (US$ Million) Table 31. Global Tofacitinib Sales Value Share by Type (2021-2026) Table 32. Global Tofacitinib Sales Value Share by Type (2027-2032) Table 33. Significant Companies of Psoriasis Table 34. Significant Companies of Rheumatoid Arthritis Table 35. Significant Companies of Ulcerative Colitis Table 36. Significant Companies of Others Table 37. Global Tofacitinib Sales Volume by Application 2021 VS 2025 VS 2032 (k pcs) Table 38. Global Tofacitinib Sales Volume by Application (2021-2026) & (k pcs) Table 39. Global Tofacitinib Sales Volume by Application (2027-2032) & (k pcs) Table 40. Global Tofacitinib Sales Volume Share by Application (2021-2026) Table 41. Global Tofacitinib Sales Volume Share by Application (2027-2032) Table 42. Global Tofacitinib Sales Value by Application 2021 VS 2025 VS 2032 (US$ Million) Table 43. Global Tofacitinib Sales Value by Application (2021-2026) & (US$ Million) Table 44. Global Tofacitinib Sales Value by Application (2027-2032) & (US$ Million) Table 45. Global Tofacitinib Sales Value Share by Application (2021-2026) Table 46. Global Tofacitinib Sales Value Share by Application (2027-2032) Table 47. Global Tofacitinib Sales by Region: 2021 VS 2025 VS 2032 (k pcs) Table 48. Global Tofacitinib Sales by Region (2021-2026) & (k pcs) Table 49. Global Tofacitinib Sales Market Share by Region (2021-2026) Table 50. Global Tofacitinib Sales by Region (2027-2032) & (k pcs) Table 51. Global Tofacitinib Sales Market Share by Region (2027-2032) Table 52. Global Tofacitinib Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 53. Global Tofacitinib Sales Value by Region (2021-2026) & (US$ Million) Table 54. Global Tofacitinib Sales Value Share by Region (2021-2026) Table 55. Global Tofacitinib Sales Value by Region (2027-2032) & (US$ Million) Table 56. Global Tofacitinib Sales Value Share by Region (2027-2032) Table 57. Global Tofacitinib Market Average Price (US$/pcs) by Region (2021-2026) Table 58. Global Tofacitinib Market Average Price (US$/pcs) by Region (2027-2032) Table 59. Global Tofacitinib Sales by Country: 2021 VS 2025 VS 2032 (k pcs) Table 60. Global Tofacitinib Sales Value by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 61. Global Tofacitinib Sales by Country (2021-2026) & (k pcs) Table 62. Global Tofacitinib Sales Market Share by Country (2021-2026) Table 63. Global Tofacitinib Sales by Country (2027-2032) & (k pcs) Table 64. Global Tofacitinib Sales Market Share by Country (2027-2032) Table 65. Global Tofacitinib Sales Value by Country (2021-2026) & (US$ Million) Table 66. Global Tofacitinib Sales Value Market Share by Country (2021-2026) Table 67. Global Tofacitinib Sales Value by Country (2027-2032) & (US$ Million) Table 68. Global Tofacitinib Sales Value Market Share by Country (2027-2032) Table 69. Pfizer Company Information Table 70. Pfizer Business Overview Table 71. Pfizer Tofacitinib Sales (k pcs), Value (US$ Million), Price (US$/pcs) and Gross Margin (2021-2026) Table 72. Pfizer Tofacitinib Product Portfolio Table 73. Pfizer Recent Development Table 74. Globe Pharmaceuticals Company Information Table 75. Globe Pharmaceuticals Business Overview Table 76. Globe Pharmaceuticals Tofacitinib Sales (k pcs), Value (US$ Million), Price (US$/pcs) and Gross Margin (2021-2026) Table 77. Globe Pharmaceuticals Tofacitinib Product Portfolio Table 78. Globe Pharmaceuticals Recent Development Table 79. Drug International Company Information Table 80. Drug International Business Overview Table 81. Drug International Tofacitinib Sales (k pcs), Value (US$ Million), Price (US$/pcs) and Gross Margin (2021-2026) Table 82. Drug International Tofacitinib Product Portfolio Table 83. Drug International Recent Development Table 84. Delta Pharma Limited Company Information Table 85. Delta Pharma Limited Business Overview Table 86. Delta Pharma Limited Tofacitinib Sales (k pcs), Value (US$ Million), Price (US$/pcs) and Gross Margin (2021-2026) Table 87. Delta Pharma Limited Tofacitinib Product Portfolio Table 88. Delta Pharma Limited Recent Development Table 89. Beacon Pharmaceuticals Company Information Table 90. Beacon Pharmaceuticals Business Overview Table 91. Beacon Pharmaceuticals Tofacitinib Sales (k pcs), Value (US$ Million), Price (US$/pcs) and Gross Margin (2021-2026) Table 92. Beacon Pharmaceuticals Tofacitinib Product Portfolio Table 93. Beacon Pharmaceuticals Recent Development Table 94. Key Raw Materials Table 95. Raw Materials Key Suppliers Table 96. Tofacitinib Distributors List Table 97. Tofacitinib Customers List Table 98. Research Programs/Design for This Report Table 99. Authors List of This Report Table 100. Secondary Sources Table 101. Primary Sources List of Figures Figure 1. Tofacitinib Product Image Figure 2. Global Tofacitinib Sales Value (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Tofacitinib Sales Value (2021-2032) & (US$ Million) Figure 4. Global Tofacitinib Sales (2021-2032) & (k pcs) Figure 5. Global Tofacitinib Sales Average Price (US$/pcs) & (2021-2032) Figure 6. Global Tofacitinib Company Revenue Ranking in 2025 (US$ Million) Figure 7. Global Top 5 and 10 Company Market Share by Revenue in 2025 (US$ Million) Figure 8. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 9. 5mg*60 Tablets Image Figure 10. 5mg*30 Tablets Image Figure 11. 5mg*14 Tablets Image Figure 12. 5mg*10 Tablets Image Figure 13. 10mg*14 Tablets Image Figure 14. 10mg*10 Tablets Image Figure 15. Global Tofacitinib Sales Volume by Type (2021 VS 2025 VS 2032) & (k pcs) Figure 16. Global Tofacitinib Sales Volume Share 2021 VS 2025 VS 2032 Figure 17. Global Tofacitinib Sales Volume Share by Type (2021-2032) Figure 18. Global Tofacitinib Sales Value by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 19. Global Tofacitinib Sales Value Share 2021 VS 2025 VS 2032 Figure 20. Global Tofacitinib Sales Value Share by Type (2021-2032) Figure 21. Psoriasis Image Figure 22. Rheumatoid Arthritis Image Figure 23. Ulcerative Colitis Image Figure 24. Others Image Figure 25. Global Tofacitinib Sales Volume by Application (2021 VS 2025 VS 2032) & (k pcs) Figure 26. Global Tofacitinib Sales Volume Share 2021 VS 2025 VS 2032 Figure 27. Global Tofacitinib Sales Volume Share by Application (2021-2032) Figure 28. Global Tofacitinib Sales Value by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 29. Global Tofacitinib Sales Value Share 2021 VS 2025 VS 2032 Figure 30. Global Tofacitinib Sales Value Share by Application (2021-2032) Figure 31. Global Tofacitinib Sales by Region: 2021 VS 2025 VS 2032 (k pcs) Figure 32. Global Tofacitinib Sales Market Share by Region: 2021 VS 2025 VS 2032 Figure 33. Global Tofacitinib Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 34. Global Tofacitinib Sales Value Share by Region: 2021 VS 2025 VS 2032 Figure 35. North America Tofacitinib Sales Value (2021-2032) & (US$ Million) Figure 36. North America Tofacitinib Sales Value Share by Country (%), 2025 VS 2032 Figure 37. Europe Tofacitinib Sales Value (2021-2032) & (US$ Million) Figure 38. Europe Tofacitinib Sales Value Share by Country (%), 2025 VS 2032 Figure 39. Asia-Pacific Tofacitinib Sales Value (2021-2032) & (US$ Million) Figure 40. Asia-Pacific Tofacitinib Sales Value Share by Country (%), 2025 VS 2032 Figure 41. South America Tofacitinib Sales Value (2021-2032) & (US$ Million) Figure 42. South America Tofacitinib Sales Value Share by Country (%), 2025 VS 2032 Figure 43. Middle East & Africa Tofacitinib Sales Value (2021-2032) & (US$ Million) Figure 44. Middle East & Africa Tofacitinib Sales Value Share by Country (%), 2025 VS 2032 Figure 45. USA Tofacitinib Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 46. USA Tofacitinib Sales Value Share by Type, 2025 VS 2032 & (%) Figure 47. USA Tofacitinib Sales Value Share by Application, 2025 VS 2032 & (%) Figure 48. Canada Tofacitinib Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 49. Canada Tofacitinib Sales Value Share by Type, 2025 VS 2032 & (%) Figure 50. Canada Tofacitinib Sales Value Share by Application, 2025 VS 2032 & (%) Figure 51. Mexico Tofacitinib Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 52. Mexico Tofacitinib Sales Value Share by Type, 2025 VS 2032 & (%) Figure 53. Mexico Tofacitinib Sales Value Share by Application, 2025 VS 2032 & (%) Figure 54. Germany Tofacitinib Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 55. Germany Tofacitinib Sales Value Share by Type, 2025 VS 2032 & (%) Figure 56. Germany Tofacitinib Sales Value Share by Application, 2025 VS 2032 & (%) Figure 57. France Tofacitinib Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 58. France Tofacitinib Sales Value Share by Type, 2025 VS 2032 & (%) Figure 59. France Tofacitinib Sales Value Share by Application, 2025 VS 2032 & (%) Figure 60. U.K. Tofacitinib Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 61. U.K. Tofacitinib Sales Value Share by Type, 2025 VS 2032 & (%) Figure 62. U.K. Tofacitinib Sales Value Share by Application, 2025 VS 2032 & (%) Figure 63. Italy Tofacitinib Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 64. Italy Tofacitinib Sales Value Share by Type, 2025 VS 2032 & (%) Figure 65. Italy Tofacitinib Sales Value Share by Application, 2025 VS 2032 & (%) Figure 66. Spain Tofacitinib Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 67. Spain Tofacitinib Sales Value Share by Type, 2025 VS 2032 & (%) Figure 68. Spain Tofacitinib Sales Value Share by Application, 2025 VS 2032 & (%) Figure 69. Russia Tofacitinib Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 70. Russia Tofacitinib Sales Value Share by Type, 2025 VS 2032 & (%) Figure 71. Russia Tofacitinib Sales Value Share by Application, 2025 VS 2032 & (%) Figure 72. Netherlands Tofacitinib Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 73. Netherlands Tofacitinib Sales Value Share by Type, 2025 VS 2032 & (%) Figure 74. Netherlands Tofacitinib Sales Value Share by Application, 2025 VS 2032 & (%) Figure 75. Nordic Countries Tofacitinib Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 76. Nordic Countries Tofacitinib Sales Value Share by Type, 2025 VS 2032 & (%) Figure 77. Nordic Countries Tofacitinib Sales Value Share by Application, 2025 VS 2032 & (%) Figure 78. China Tofacitinib Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 79. China Tofacitinib Sales Value Share by Type, 2025 VS 2032 & (%) Figure 80. China Tofacitinib Sales Value Share by Application, 2025 VS 2032 & (%) Figure 81. Japan Tofacitinib Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 82. Japan Tofacitinib Sales Value Share by Type, 2025 VS 2032 & (%) Figure 83. Japan Tofacitinib Sales Value Share by Application, 2025 VS 2032 & (%) Figure 84. South Korea Tofacitinib Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 85. South Korea Tofacitinib Sales Value Share by Type, 2025 VS 2032 & (%) Figure 86. South Korea Tofacitinib Sales Value Share by Application, 2025 VS 2032 & (%) Figure 87. India Tofacitinib Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 88. India Tofacitinib Sales Value Share by Type, 2025 VS 2032 & (%) Figure 89. India Tofacitinib Sales Value Share by Application, 2025 VS 2032 & (%) Figure 90. Australia Tofacitinib Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 91. Australia Tofacitinib Sales Value Share by Type, 2025 VS 2032 & (%) Figure 92. Australia Tofacitinib Sales Value Share by Application, 2025 VS 2032 & (%) Figure 93. Southeast Asia Tofacitinib Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 94. Southeast Asia Tofacitinib Sales Value Share by Type, 2025 VS 2032 & (%) Figure 95. Southeast Asia Tofacitinib Sales Value Share by Application, 2025 VS 2032 & (%) Figure 96. Brazil Tofacitinib Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 97. Brazil Tofacitinib Sales Value Share by Type, 2025 VS 2032 & (%) Figure 98. Brazil Tofacitinib Sales Value Share by Application, 2025 VS 2032 & (%) Figure 99. Argentina Tofacitinib Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 100. Argentina Tofacitinib Sales Value Share by Type, 2025 VS 2032 & (%) Figure 101. Argentina Tofacitinib Sales Value Share by Application, 2025 VS 2032 & (%) Figure 102. Chile Tofacitinib Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 103. Chile Tofacitinib Sales Value Share by Type, 2025 VS 2032 & (%) Figure 104. Chile Tofacitinib Sales Value Share by Application, 2025 VS 2032 & (%) Figure 105. Colombia Tofacitinib Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 106. Colombia Tofacitinib Sales Value Share by Type, 2025 VS 2032 & (%) Figure 107. Colombia Tofacitinib Sales Value Share by Application, 2025 VS 2032 & (%) Figure 108. Peru Tofacitinib Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 109. Peru Tofacitinib Sales Value Share by Type, 2025 VS 2032 & (%) Figure 110. Peru Tofacitinib Sales Value Share by Application, 2025 VS 2032 & (%) Figure 111. Saudi Arabia Tofacitinib Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 112. Saudi Arabia Tofacitinib Sales Value Share by Type, 2025 VS 2032 & (%) Figure 113. Saudi Arabia Tofacitinib Sales Value Share by Application, 2025 VS 2032 & (%) Figure 114. Israel Tofacitinib Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 115. Israel Arabia Tofacitinib Sales Value Share by Type, 2025 VS 2032 & (%) Figure 116. Israel Arabia Tofacitinib Sales Value Share by Application, 2025 VS 2032 & (%) Figure 117. UAE Tofacitinib Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 118. UAE Tofacitinib Sales Value Share by Type, 2025 VS 2032 & (%) Figure 119. UAE Tofacitinib Sales Value Share by Application, 2025 VS 2032 & (%) Figure 120. Turkey Tofacitinib Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 121. Turkey Tofacitinib Sales Value Share by Type, 2025 VS 2032 & (%) Figure 122. Turkey Tofacitinib Sales Value Share by Application, 2025 VS 2032 & (%) Figure 123. Iran Tofacitinib Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 124. Iran Tofacitinib Sales Value Share by Type, 2025 VS 2032 & (%) Figure 125. Iran Tofacitinib Sales Value Share by Application, 2025 VS 2032 & (%) Figure 126. Egypt Tofacitinib Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 127. Egypt Tofacitinib Sales Value Share by Type, 2025 VS 2032 & (%) Figure 128. Egypt Tofacitinib Sales Value Share by Application, 2025 VS 2032 & (%) Figure 129. Tofacitinib Value Chain Figure 130. Manufacturing Cost Structure Figure 131. Tofacitinib Sales Mode & Process Figure 132. Direct Comparison with Distribution Share Figure 133. Distributors Profiles Figure 134. Years Considered Figure 135. Research Process Figure 136. Key Executives Interviewed

Scope & coverage.

Types
  • 5mg*60 Tablets
  • 5mg*30 Tablets
  • 5mg*14 Tablets
  • 5mg*10 Tablets
  • 10mg*14 Tablets
  • 10mg*10 Tablets
Applications
  • Psoriasis
  • Rheumatoid Arthritis
  • Ulcerative Colitis
  • Others
Companies covered
  • Pfizer
  • Globe Pharmaceuticals
  • Drug International
  • Delta Pharma Limited
  • Beacon Pharmaceuticals

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Market Growth Prospects
  3. 1.2.1 Global Tofacitinib Sales Value (2021-2032)
  4. 1.2.2 Global Tofacitinib Sales Volume (2021-2032)
  5. 1.2.3 Global Tofacitinib Sales Average Price (2021-2032)
  6. 1.3 Assumptions and Limitations
  7. 1.4 Study Goals and Objectives
2 Tofacitinib Market Dynamics
  1. 2.1 Tofacitinib Industry Trends
  2. 2.2 Tofacitinib Industry Drivers
  3. 2.3 Tofacitinib Industry Opportunities and Challenges
  4. 2.4 Tofacitinib Industry Restraints
3 Tofacitinib Market by Company
  1. 3.1 Global Tofacitinib Company Revenue Ranking in 2025
  2. 3.2 Global Tofacitinib Revenue by Company (2021-2026)
  3. 3.3 Global Tofacitinib Sales Volume by Company (2021-2026)
  4. 3.4 Global Tofacitinib Average Price by Company (2021-2026)
  5. 3.5 Global Tofacitinib Company Ranking (2024-2026)
  6. 3.6 Global Tofacitinib Company Manufacturing Base and Headquarters
  7. 3.7 Global Tofacitinib Company Product Type and Application
  8. 3.8 Global Tofacitinib Company Establishment Date
  9. 3.9 Market Competitive Analysis
  10. 3.9.1 Global Tofacitinib Market Concentration Ratio (CR5 and HHI)
  11. 3.9.2 Global Top 5 and 10 Company Market Share by Revenue in 2025
  12. 3.9.3 2025 Tofacitinib Tier 1, Tier 2, and Tier 3 Companies
  13. 3.10 Mergers and Acquisitions Expansion
4 Tofacitinib Market by Type
  1. 4.1 Tofacitinib Type Introduction
  2. 4.1.1 5mg*60 Tablets
  3. 4.1.2 5mg*30 Tablets
  4. 4.1.3 5mg*14 Tablets
  5. 4.1.4 5mg*10 Tablets
  6. 4.1.5 10mg*14 Tablets
  7. 4.1.6 10mg*10 Tablets
  8. 4.2 Global Tofacitinib Sales Volume by Type
  9. 4.2.1 Global Tofacitinib Sales Volume by Type (2021 VS 2025 VS 2032)
  10. 4.2.2 Global Tofacitinib Sales Volume by Type (2021-2032)
  11. 4.2.3 Global Tofacitinib Sales Volume Share by Type (2021-2032)
  12. 4.3 Global Tofacitinib Sales Value by Type
  13. 4.3.1 Global Tofacitinib Sales Value by Type (2021 VS 2025 VS 2032)
  14. 4.3.2 Global Tofacitinib Sales Value by Type (2021-2032)
  15. 4.3.3 Global Tofacitinib Sales Value Share by Type (2021-2032)
5 Tofacitinib Market by Application
  1. 5.1 Tofacitinib Application Introduction
  2. 5.1.1 Psoriasis
  3. 5.1.2 Rheumatoid Arthritis
  4. 5.1.3 Ulcerative Colitis
  5. 5.1.4 Others
  6. 5.2 Global Tofacitinib Sales Volume by Application
  7. 5.2.1 Global Tofacitinib Sales Volume by Application (2021 VS 2025 VS 2032)
  8. 5.2.2 Global Tofacitinib Sales Volume by Application (2021-2032)
  9. 5.2.3 Global Tofacitinib Sales Volume Share by Application (2021-2032)
  10. 5.3 Global Tofacitinib Sales Value by Application
  11. 5.3.1 Global Tofacitinib Sales Value by Application (2021 VS 2025 VS 2032)
  12. 5.3.2 Global Tofacitinib Sales Value by Application (2021-2032)
  13. 5.3.3 Global Tofacitinib Sales Value Share by Application (2021-2032)
6 Tofacitinib Regional Sales and Value Analysis
  1. 6.1 Global Tofacitinib Sales by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global Tofacitinib Sales by Region (2021-2032)
  3. 6.2.1 Global Tofacitinib Sales by Region: 2021-2026
  4. 6.2.2 Global Tofacitinib Sales by Region (2027-2032)
  5. 6.3 Global Tofacitinib Sales Value by Region: 2021 VS 2025 VS 2032
  6. 6.4 Global Tofacitinib Sales Value by Region (2021-2032)
  7. 6.4.1 Global Tofacitinib Sales Value by Region: 2021-2026
  8. 6.4.2 Global Tofacitinib Sales Value by Region (2027-2032)
  9. 6.5 Global Tofacitinib Market Price Analysis by Region (2021-2026)
  10. 6.6 North America
  11. 6.6.1 North America Tofacitinib Sales Value (2021-2032)
  12. 6.6.2 North America Tofacitinib Sales Value Share by Country, 2025 VS 2032
  13. 6.7 Europe
  14. 6.7.1 Europe Tofacitinib Sales Value (2021-2032)
  15. 6.7.2 Europe Tofacitinib Sales Value Share by Country, 2025 VS 2032
  16. 6.8 Asia-Pacific
  17. 6.8.1 Asia-Pacific Tofacitinib Sales Value (2021-2032)
  18. 6.8.2 Asia-Pacific Tofacitinib Sales Value Share by Country, 2025 VS 2032
  19. 6.9 South America
  20. 6.9.1 South America Tofacitinib Sales Value (2021-2032)
  21. 6.9.2 South America Tofacitinib Sales Value Share by Country, 2025 VS 2032
  22. 6.10 Middle East & Africa
  23. 6.10.1 Middle East & Africa Tofacitinib Sales Value (2021-2032)
  24. 6.10.2 Middle East & Africa Tofacitinib Sales Value Share by Country, 2025 VS 2032
7 Tofacitinib Country-level Sales and Value Analysis
  1. 7.1 Global Tofacitinib Sales by Country: 2021 VS 2025 VS 2032
  2. 7.2 Global Tofacitinib Sales Value by Country: 2021 VS 2025 VS 2032
  3. 7.3 Global Tofacitinib Sales by Country (2021-2032)
  4. 7.3.1 Global Tofacitinib Sales by Country (2021-2026)
  5. 7.3.2 Global Tofacitinib Sales by Country (2027-2032)
  6. 7.4 Global Tofacitinib Sales Value by Country (2021-2032)
  7. 7.4.1 Global Tofacitinib Sales Value by Country (2021-2026)
  8. 7.4.2 Global Tofacitinib Sales Value by Country (2027-2032)
  9. 7.5 USA
  10. 7.5.1 USA Tofacitinib Sales Value Growth Rate (2021-2032)
  11. 7.5.2 USA Tofacitinib Sales Value Share by Type, 2025 VS 2032
  12. 7.5.3 USA Tofacitinib Sales Value Share by Application, 2025 VS 2032
  13. 7.6 Canada
  14. 7.6.1 Canada Tofacitinib Sales Value Growth Rate (2021-2032)
  15. 7.6.2 Canada Tofacitinib Sales Value Share by Type, 2025 VS 2032
  16. 7.6.3 Canada Tofacitinib Sales Value Share by Application, 2025 VS 2032
  17. 7.7 Mexico
  18. 7.6.1 Mexico Tofacitinib Sales Value Growth Rate (2021-2032)
  19. 7.6.2 Mexico Tofacitinib Sales Value Share by Type, 2025 VS 2032
  20. 7.6.3 Mexico Tofacitinib Sales Value Share by Application, 2025 VS 2032
  21. 7.8 Germany
  22. 7.8.1 Germany Tofacitinib Sales Value Growth Rate (2021-2032)
  23. 7.8.2 Germany Tofacitinib Sales Value Share by Type, 2025 VS 2032
  24. 7.8.3 Germany Tofacitinib Sales Value Share by Application, 2025 VS 2032
  25. 7.9 France
  26. 7.9.1 France Tofacitinib Sales Value Growth Rate (2021-2032)
  27. 7.9.2 France Tofacitinib Sales Value Share by Type, 2025 VS 2032
  28. 7.9.3 France Tofacitinib Sales Value Share by Application, 2025 VS 2032
  29. 7.10 U.K.
  30. 7.10.1 U.K. Tofacitinib Sales Value Growth Rate (2021-2032)
  31. 7.10.2 U.K. Tofacitinib Sales Value Share by Type, 2025 VS 2032
  32. 7.10.3 U.K. Tofacitinib Sales Value Share by Application, 2025 VS 2032
  33. 7.11 Italy
  34. 7.11.1 Italy Tofacitinib Sales Value Growth Rate (2021-2032)
  35. 7.11.2 Italy Tofacitinib Sales Value Share by Type, 2025 VS 2032
  36. 7.11.3 Italy Tofacitinib Sales Value Share by Application, 2025 VS 2032
  37. 7.12 Spain
  38. 7.12.1 Spain Tofacitinib Sales Value Growth Rate (2021-2032)
  39. 7.12.2 Spain Tofacitinib Sales Value Share by Type, 2025 VS 2032
  40. 7.12.3 Spain Tofacitinib Sales Value Share by Application, 2025 VS 2032
  41. 7.13 Russia
  42. 7.13.1 Russia Tofacitinib Sales Value Growth Rate (2021-2032)
  43. 7.13.2 Russia Tofacitinib Sales Value Share by Type, 2025 VS 2032
  44. 7.13.3 Russia Tofacitinib Sales Value Share by Application, 2025 VS 2032
  45. 7.14 Netherlands
  46. 7.14.1 Netherlands Tofacitinib Sales Value Growth Rate (2021-2032)
  47. 7.14.2 Netherlands Tofacitinib Sales Value Share by Type, 2025 VS 2032
  48. 7.14.3 Netherlands Tofacitinib Sales Value Share by Application, 2025 VS 2032
  49. 7.15 Nordic Countries
  50. 7.15.1 Nordic Countries Tofacitinib Sales Value Growth Rate (2021-2032)
  51. 7.15.2 Nordic Countries Tofacitinib Sales Value Share by Type, 2025 VS 2032
  52. 7.15.3 Nordic Countries Tofacitinib Sales Value Share by Application, 2025 VS 2032
  53. 7.16 China
  54. 7.16.1 China Tofacitinib Sales Value Growth Rate (2021-2032)
  55. 7.16.2 China Tofacitinib Sales Value Share by Type, 2025 VS 2032
  56. 7.16.3 China Tofacitinib Sales Value Share by Application, 2025 VS 2032
  57. 7.17 Japan
  58. 7.17.1 Japan Tofacitinib Sales Value Growth Rate (2021-2032)
  59. 7.17.2 Japan Tofacitinib Sales Value Share by Type, 2025 VS 2032
  60. 7.17.3 Japan Tofacitinib Sales Value Share by Application, 2025 VS 2032
  61. 7.18 South Korea
  62. 7.18.1 South Korea Tofacitinib Sales Value Growth Rate (2021-2032)
  63. 7.18.2 South Korea Tofacitinib Sales Value Share by Type, 2025 VS 2032
  64. 7.18.3 South Korea Tofacitinib Sales Value Share by Application, 2025 VS 2032
  65. 7.19 India
  66. 7.19.1 India Tofacitinib Sales Value Growth Rate (2021-2032)
  67. 7.19.2 India Tofacitinib Sales Value Share by Type, 2025 VS 2032
  68. 7.19.3 India Tofacitinib Sales Value Share by Application, 2025 VS 2032
  69. 7.20 Australia
  70. 7.20.1 Australia Tofacitinib Sales Value Growth Rate (2021-2032)
  71. 7.20.2 Australia Tofacitinib Sales Value Share by Type, 2025 VS 2032
  72. 7.20.3 Australia Tofacitinib Sales Value Share by Application, 2025 VS 2032
  73. 7.21 Southeast Asia
  74. 7.21.1 Southeast Asia Tofacitinib Sales Value Growth Rate (2021-2032)
  75. 7.21.2 Southeast Asia Tofacitinib Sales Value Share by Type, 2025 VS 2032
  76. 7.21.3 Southeast Asia Tofacitinib Sales Value Share by Application, 2025 VS 2032
  77. 7.22 Brazil
  78. 7.22.1 Brazil Tofacitinib Sales Value Growth Rate (2021-2032)
  79. 7.22.2 Brazil Tofacitinib Sales Value Share by Type, 2025 VS 2032
  80. 7.22.3 Brazil Tofacitinib Sales Value Share by Application, 2025 VS 2032
  81. 7.23 Argentina
  82. 7.23.1 Argentina Tofacitinib Sales Value Growth Rate (2021-2032)
  83. 7.23.2 Argentina Tofacitinib Sales Value Share by Type, 2025 VS 2032
  84. 7.23.3 Argentina Tofacitinib Sales Value Share by Application, 2025 VS 2032
  85. 7.24 Chile
  86. 7.24.1 Chile Tofacitinib Sales Value Growth Rate (2021-2032)
  87. 7.24.2 Chile Tofacitinib Sales Value Share by Type, 2025 VS 2032
  88. 7.24.3 Chile Tofacitinib Sales Value Share by Application, 2025 VS 2032
  89. 7.25 Colombia
  90. 7.25.1 Colombia Tofacitinib Sales Value Growth Rate (2021-2032)
  91. 7.25.2 Colombia Tofacitinib Sales Value Share by Type, 2025 VS 2032
  92. 7.25.3 Colombia Tofacitinib Sales Value Share by Application, 2025 VS 2032
  93. 7.26 Peru
  94. 7.26.1 Peru Tofacitinib Sales Value Growth Rate (2021-2032)
  95. 7.26.2 Peru Tofacitinib Sales Value Share by Type, 2025 VS 2032
  96. 7.26.3 Peru Tofacitinib Sales Value Share by Application, 2025 VS 2032
  97. 7.27 Saudi Arabia
  98. 7.27.1 Saudi Arabia Tofacitinib Sales Value Growth Rate (2021-2032)
  99. 7.27.2 Saudi Arabia Tofacitinib Sales Value Share by Type, 2025 VS 2032
  100. 7.27.3 Saudi Arabia Tofacitinib Sales Value Share by Application, 2025 VS 2032
  101. 7.28 Israel
  102. 7.28.1 Israel Tofacitinib Sales Value Growth Rate (2021-2032)
  103. 7.28.2 Israel Tofacitinib Sales Value Share by Type, 2025 VS 2032
  104. 7.28.3 Israel Tofacitinib Sales Value Share by Application, 2025 VS 2032
  105. 7.29 UAE
  106. 7.29.1 UAE Tofacitinib Sales Value Growth Rate (2021-2032)
  107. 7.29.2 UAE Tofacitinib Sales Value Share by Type, 2025 VS 2032
  108. 7.29.3 UAE Tofacitinib Sales Value Share by Application, 2025 VS 2032
  109. 7.30 Turkey
  110. 7.30.1 Turkey Tofacitinib Sales Value Growth Rate (2021-2032)
  111. 7.30.2 Turkey Tofacitinib Sales Value Share by Type, 2025 VS 2032
  112. 7.30.3 Turkey Tofacitinib Sales Value Share by Application, 2025 VS 2032
  113. 7.31 Iran
  114. 7.31.1 Iran Tofacitinib Sales Value Growth Rate (2021-2032)
  115. 7.31.2 Iran Tofacitinib Sales Value Share by Type, 2025 VS 2032
  116. 7.31.3 Iran Tofacitinib Sales Value Share by Application, 2025 VS 2032
  117. 7.32 Egypt
  118. 7.32.1 Egypt Tofacitinib Sales Value Growth Rate (2021-2032)
  119. 7.32.2 Egypt Tofacitinib Sales Value Share by Type, 2025 VS 2032
  120. 7.32.3 Egypt Tofacitinib Sales Value Share by Application, 2025 VS 2032
8 Company Profiles
  1. 8.1 Pfizer
  2. 8.1.1 Pfizer Company Information
  3. 8.1.2 Pfizer Business Overview
  4. 8.1.3 Pfizer Tofacitinib Sales, Value and Gross Margin (2021-2026)
  5. 8.1.4 Pfizer Tofacitinib Product Portfolio
  6. 8.1.5 Pfizer Recent Developments
  7. 8.2 Globe Pharmaceuticals
  8. 8.2.1 Globe Pharmaceuticals Company Information
  9. 8.2.2 Globe Pharmaceuticals Business Overview
  10. 8.2.3 Globe Pharmaceuticals Tofacitinib Sales, Value and Gross Margin (2021-2026)
  11. 8.2.4 Globe Pharmaceuticals Tofacitinib Product Portfolio
  12. 8.2.5 Globe Pharmaceuticals Recent Developments
  13. 8.3 Drug International
  14. 8.3.1 Drug International Company Information
  15. 8.3.2 Drug International Business Overview
  16. 8.3.3 Drug International Tofacitinib Sales, Value and Gross Margin (2021-2026)
  17. 8.3.4 Drug International Tofacitinib Product Portfolio
  18. 8.3.5 Drug International Recent Developments
  19. 8.4 Delta Pharma Limited
  20. 8.4.1 Delta Pharma Limited Company Information
  21. 8.4.2 Delta Pharma Limited Business Overview
  22. 8.4.3 Delta Pharma Limited Tofacitinib Sales, Value and Gross Margin (2021-2026)
  23. 8.4.4 Delta Pharma Limited Tofacitinib Product Portfolio
  24. 8.4.5 Delta Pharma Limited Recent Developments
  25. 8.5 Beacon Pharmaceuticals
  26. 8.5.1 Beacon Pharmaceuticals Company Information
  27. 8.5.2 Beacon Pharmaceuticals Business Overview
  28. 8.5.3 Beacon Pharmaceuticals Tofacitinib Sales, Value and Gross Margin (2021-2026)
  29. 8.5.4 Beacon Pharmaceuticals Tofacitinib Product Portfolio
  30. 8.5.5 Beacon Pharmaceuticals Recent Developments
9 Value Chain and Sales Channels Analysis
  1. 9.1 Tofacitinib Value Chain Analysis
  2. 9.1.1 Tofacitinib Key Raw Materials
  3. 9.1.2 Raw Materials Key Suppliers
  4. 9.1.3 Manufacturing Cost Structure
  5. 9.1.4 Tofacitinib Sales Mode & Process
  6. 9.2 Tofacitinib Sales Channels Analysis
  7. 9.2.1 Direct Comparison with Distribution Share
  8. 9.2.2 Tofacitinib Distributors
  9. 9.2.3 Tofacitinib Customers
10 Concluding Insights
    11 Appendix
    1. 11.1 Reasons for Doing This Study
    2. 11.2 Research Methodology
    3. 11.3 Research Process
    4. 11.4 Authors List of This Report
    5. 11.5 Data Source
    6. 11.5.1 Secondary Sources
    7. 11.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,250USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst